Opko Health Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Consolidated Total Revenue Quarterly124.2MTarget: 530000000 to 560000000
Diagnostics Segment Revenue Quarterly72.2MTarget: 300000000 to 312000000
NGENLA Gross Profit Share Quarterly6.4MTarget: 34000000 to 37000000
Watch Items
- Diagnostics Segment Breakeven TimelineTrigger: Operating loss narrowing to zero by mid-2026Action: Monitor quarterly segment operating income and cost reduction initiatives at BioReference Laboratories.
- ModeX Therapeutics Pipeline ProgressTrigger: Initiation of Phase 1 clinical trials or milestone achievements for MDX2301 and other multispecific candidatesAction: Track clinical trial updates, regulatory filings, and partner-funded R&D milestones.
Research as of 19 Jun 2026